Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Canada's Graduate Scholarship-Master's Program

EF 2023-24

Résumé
Obesity is an epidemic that continues to increase worldwide. Few pharmacological interventions exist to combat it, due to low clinical efficacy and safety concerns. Contrave is an anti-obesity drug that was approved by the Food and Drug Administration in 2014 for clinical use. Contrave contains two active components, naltrexone and bupropion, which are thought to act on cells within the hypothalamus in the brain to promote satiation and increase energy expenditure. Despite having been on the market for 9 years, the neural effects of Contrave in humans remains unknown. Considering that Contrave likely exerts its effects by targeting the hypothalamus and dopamine circuits, I propose that it also likely modifies neural activity in the reward, cognitive control, and appetitive networks, which are known to be disrupted in obese individuals. As such, my objective is to compare brain activity in areas within the reward, cognitive control, and appetitive networks in people with obesity during a randomized, double-blind, and placebo controlled 4-week Contrave intervention. To investigate the effects of Contrave, a 12-minute functional magnetic resonance imaging (fMRI) task will be used to compare brain activity before and after the 4-week intervention. This task follows that of previous obesity-related fMRI research, and will involve prompting participants with high-calorie food images, low-calorie food images, and neutral control images. This study will be pivotal in understanding how Contrave affects brain activity profiles, and further a general understanding of neural features in obesity. I also hope that this research can improve Contrave's clinical use, as well as obesity-related patient care.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506558
Name
Woytowicz Lauren J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Canada's Graduate Scholarship-Master's Program
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Appetite; Bupropion; Clinical Trial; Cognitive Control; Contrave; Functional Magnetic Resonance Imaging; Naltrexone; Neuroscience; Obesity; Reward
Abstract
Obesity is an epidemic that continues to increase worldwide. Few pharmacological interventions exist to combat it, due to low clinical efficacy and safety concerns. Contrave is an anti-obesity drug that was approved by the Food and Drug Administration in 2014 for clinical use. Contrave contains two active components, naltrexone and bupropion, which are thought to act on cells within the hypothalamus in the brain to promote satiation and increase energy expenditure. Despite having been on the market for 9 years, the neural effects of Contrave in humans remains unknown. Considering that Contrave likely exerts its effects by targeting the hypothalamus and dopamine circuits, I propose that it also likely modifies neural activity in the reward, cognitive control, and appetitive networks, which are known to be disrupted in obese individuals. As such, my objective is to compare brain activity in areas within the reward, cognitive control, and appetitive networks in people with obesity during a randomized, double-blind, and placebo controlled 4-week Contrave intervention. To investigate the effects of Contrave, a 12-minute functional magnetic resonance imaging (fMRI) task will be used to compare brain activity before and after the 4-week intervention. This task follows that of previous obesity-related fMRI research, and will involve prompting participants with high-calorie food images, low-calorie food images, and neutral control images. This study will be pivotal in understanding how Contrave affects brain activity profiles, and further a general understanding of neural features in obesity. I also hope that this research can improve Contrave's clinical use, as well as obesity-related patient care.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Woytowicz, Lauren J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~